Resverlogix Extends Debenture, Adjusts Interest Rate
Company Announcements

Resverlogix Extends Debenture, Adjusts Interest Rate

Resverlogix Corp. (TSE:RVX) has released an update.

Resverlogix Corp. has announced a strategic financial maneuver by extending their US$6.0 million debenture with Hepalink for an additional two years, now maturing on May 13, 2026, while also removing Hepalink’s conversion rights and increasing the interest rate from 12% to 18%. The company, a leader in epigenetic therapies, is working towards advancing treatments for cardiovascular disease and other chronic conditions. The amendment awaits formal documentation and approvals, including the nod from the Toronto Stock Exchange.

For further insights into TSE:RVX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskResverlogix Showcases Apabetalone’s Heart Health Benefits
TipRanks Canadian Auto-Generated NewsdeskResverlogix Secures Shareholder Approval and Debenture Extension
TipRanks Canadian Auto-Generated NewsdeskResverlogix Amends Debenture Terms Amidst Therapy Development
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App